Antiretroviral drug resistance and routine therapy, Cameroon

被引：25

作者：

Laurent, C ^{[1
]}

Kouanfack, C

Vergne, L

Tardy, M

Zekeng, L

Noumsi, N

Butel, C

Bourgeois, A

Mpoudi-Ngolé, E

Koulla-Shiro, S

Peeters, M

Delaporte, E

机构：

[1] Inst Rech Dev, UMR 145, Montpellier, France

[2] Cent Hosp, Yaounde, Cameroon

[3] Lab Sante Hyg Mobile, Yaounde, Cameroon

[4] Natl AIDS Program, Yaounde, Cameroon

[5] Mil Hosp, Yaounde, Cameroon

来源：

EMERGING INFECTIOUS DISEASES | 2006年 / 12卷 / 06期

关键词：

D O I：

10.3201/eid1206.050860

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Among 128 patients routinely receiving highly active antiretroviral therapy in an HIV/AIDS outpatient clinic in Cameroon, 16.4% had drug resistance after a median of 10 months. Of these, 12.5% had resistance to nucleoside reverse transcriptase inhibitors (NRTIs), 10.2% to non-NRTIs, and 2.3% to protease inhibitors.

引用

页码：1001 / 1004

页数：4

共 12 条

[1]

Adjé C, 2001, J ACQ IMMUN DEF SYND, V26, P501, DOI 10.1097/00126334-200104150-00018

[2]

Bourgeois A, 2005, ANTIVIR THER, V10, P335

[3] Adherence to HAART and its principal determinants in a cohort of Senegalese adults [J].

Lanièce, I ;

Ciss, M ;

Desclaux, A ;

Diop, K ;

Mbodj, F ;

Ndiaye, B ;

Sylla, O ;

Delaporte, E ;

Ndoye, I .

AIDS, 2003, 17 :S103-S108

[4] Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon:: open-label multicentre trial [J].

Laurent, C ;

Kouanfack, C ;

Koulla-Shiro, S ;

Nkoué, N ;

Bourgeois, A ;

Calmy, A ;

Lactuock, B ;

Nzeusseu, V ;

Mougnutou, R ;

Peytavin, G ;

Liégeois, F ;

Nerrienet, E ;

Tardy, M ;

Peeters, M ;

Andrieux-Meyer, I ;

Zekeng, L ;

Kazatchkine, M ;

Mpoudi-Ngolé, E ;

Delaporte, E .

LANCET, 2004, 364 (9428) :29-34

[5] Antiretroviral therapy in public and private routine health care clinics in Cameroon:: Lessons from the Douala antiretroviral (DARVIR) initiative [J].

Laurent, C ;

Meilo, H ;

Guiard-Schmid, JB ;

Mapouré, Y ;

Noël, JM ;

M'Bangué, M ;

Joko, A ;

Rozenbaum, W ;

Ntoné, FN ;

Delaporte, E .

CLINICAL INFECTIOUS DISEASES, 2005, 41 (01) :108-111

[6] High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1 [J].

Richard, N ;

Juntilla, M ;

Abraha, A ;

Demers, K ;

Paxinos, E ;

Galovich, J ;

Petropoulos, C ;

Whalen, CC ;

Kyeyune, F ;

Atwine, D ;

Kityo, C ;

Mugyenyi, P ;

Arts, EJ .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (04) :355-364

[7] Antiretroviral therapy in Africa [J].

Stevens, W ;

Kaye, S ;

Corrah, T .

BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7434) :280-282

[8] Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy [J].

Vergne, L ;

Kane, CT ;

Laurent, C ;

Diakhaté, N ;

Gueye, NFN ;

Gueye, PM ;

Sow, PS ;

Faye, MA ;

Liégeois, F ;

Ndir, A ;

Lanièce, I ;

Peeters, M ;

Ndoye, I ;

Mboup, S ;

Delaporte, E .

AIDS, 2003, 17 :S31-S38

[9] Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage [J].

Vergne, L ;

Bourgeois, A ;

Mpoudi-Ngole, E ;

Mougnutou, R ;

Mbuagbaw, J ;

Liegeois, F ;

Laurent, C ;

Butel, C ;

Zekeng, L ;

Delaporte, E ;

Peeters, M .

VIROLOGY, 2003, 310 (02) :254-266

[10] Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients [J].

Vergne, L ;

Peeters, M ;

Mpoudi-Ngole, E ;

Bourgeois, A ;

Liegeois, F ;

Toure-Kane, C ;

Mboup, S ;

Mulanga-Kabeya, C ;

Saman, E ;

Jourdan, J ;

Reynes, J ;

Delaporte, E .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (11) :3919-3925

← 1 2 →